Skip to main content
. 2021 Sep 29;9(2):e00391-21. doi: 10.1128/Spectrum.00391-21

Appendix 1B.

COVID-19 related characteristics of participants tested, by serology assay

Parameter Abbott SARS-CoV-2 IgG
Roche Anti-SARS-CoV-2
Wantai SARS-CoV-2 Antibody ELISA
Total participants
n % n % n % n %
Total participants tested 5,788 5,787 485 5,788
Close contact with a case of COVID-19
 Yes 1,705 29.5 1,704 29.4 258 53.2 1,705 29.5
 No 4,071 70.3 4,071 70.3 225 46.4 4,071 70.3
 Unknown 12 0.2 12 0.2 2 0.4 12 0.2
Main type of patient contacta
 Daily contact with known/suspected COVID-19 patients 903 15.6 902 15.6 109 22.5 903 15.6
 Daily contact with patients without COVID-19 3,245 56.1 3,245 56.1 299 61.6 3,245 56.1
 No patient contact 1,635 28.2 1,635 28.3 77 15.9 1,635 28.2
 Unknown 5 0.1 5 0.1 0 0.0 5 0.1
Previous COVID-19 symptoms (ever)
 No symptoms 2,869 49.6 2,868 49.6 102 21.0 2,869 49.6
 Had symptoms 2911 50.3 2,911 50.3 381 78.6 2,911 50.3
 Unknown 8 0.1 8 0.1 2 0.4 8 0.1
Severity of symptoms
 Minor symptoms 2,159 74.2 2,159 74.2 193 50.7 2,159 74.2
 Significant symptoms 701 24.1 701 24.1 161 42.3 701 24.1
 Severe symptoms (hospitalized) 51 1.8 51 1.8 27 7.1 51 1.8
Previous COVID-19 PCR test
 Yes 2,779 48.0 2,778 48.0 380 78.4 2,779 48.0
 No 3,003 51.9 3,003 51.9 105 21.6 3,003 51.9
 Unknown 6 0.1 6 0.1 0 0.0 6 0.1
Previous positive COVID-19 PCR test
 Yes 367 6.3 367 6.3 259 53.4 367 6.3
 No 5,415 93.6 5,414 93.6 226 46.6 5,415 93.6
 Unknown 6 0.1 6 0.1 0 0.0 6 0.1
a

Participants were asked which one describes most of their current work.